Drug Information Association Logo

INNOVATION THROUGH PUBLIC PRIVATE PARTNERSHIP COLLABORATIONS

Track:
Innovation in R&D Models

Day & Time:
March 26, 11:00AM - 12:30PM (Central European Standard Time)

Session Number:
1402

Room Number:
Room NO

Type:
Session

Title:
INNOVATION THROUGH PUBLIC PRIVATE PARTNERSHIP COLLABORATIONS

Chair(s):
Salah-Dine Chibout, PhD
Head of Exploratory Development Europe. Global Head Investigative Toxicology
Novartis Pharma AG, Switzerland

Description:
Modern information and communication technologies are reinforcing and expanding PPPs beyond all previous limitations and boundaries. Together with the insight that certain innovations are unfeasible without inter-organisational collaboration today PPP programs hold a great promise. Outcomes of the largest EU PPP program, IMI, will be discussed. In addition, legal, IP and collaboration management aspects within such large scale PPPs will be addressed.

Presentation(s) & Speaker(s):
IMI as a European Flagship to Address Major Health Challenges
Michel Goldman, MD, PhD
Executive Director
Innovative Medicines Initiative (IMI), Belgium

Initiatives and Challenges for Creating Innovative Drugs
Hideaki Ui, PhD
Director, Division of Planning & Coordination, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Biomarker Qualification for Drug-Induced Injury to Kidney, Liver and the Vascular System within IMI SAFE-T Project
Thomas Joos
Deputy Managing Director
NMI Natural and Medical Sciences Institute at the University of Tübingen, Germany

US Perspective on Public-Private Partnerships
Diane Stephenson
Associate Director, CAMD
Critical Path Institute, United States